Holly M McCabe1, Alannah Smrke2, Fiona Cowie3, Jeff White3, Peter Chong4, Steven Lo5, Ashish Mahendra5, Sanjay Gupta5, Michelle Ferguson6, David Boddie7, Walter Mmekka8, Lorraine Stirling3, Lindsay Campbell3, Robin L Jones2,9, Ioanna Nixon1,3. 1. Department of Management Science, University of Strathclyde, Glasgow, United Kingdom. 2. The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom. 3. Scottish Sarcoma Network, The Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom. 4. Scottish Sarcoma Network, Gartnavel General Hospital, Glasgow, United Kingdom. 5. Scottish Sarcoma Network, Glasgow Royal Infirmary, Glasgow, United Kingdom. 6. Scottish Sarcoma Network, Ninewells Hospital, Dundee, United Kingdom. 7. Scottish Sarcoma Network, Aberdeen Royal Infirmary, Aberdeen, United Kingdom. 8. Scottish Sarcoma Network, Raigmore Hospital, Inverness, United Kingdom. 9. The Institute of Cancer Research, London, United Kingdom.
Abstract
PURPOSE: In Scotland, approximately 350 sarcoma cases are diagnosed per year and treated in one of the five specialist centers. Many patients are required to travel long distances to access specialist care. The COVID-19 pandemic brought a number of rapid changes into the care for patients with cancer, with increasing utilization of telemedicine. We aimed to evaluate how the utilization of telemedicine affects professionals and patients across Scotland and care delivery, at the Beatson West of Scotland Cancer Centre Sarcoma Unit. METHODS: Between June 8 and August 25, 2020, we invited patients and professional sarcoma multidisciplinary team members to participate in separate online anonymous survey questionnaires, to assess their attitudes toward telemedicine. Data were extracted, and descriptive statistics were performed. RESULTS: Patient satisfaction (n = 64) with telemedicine was high (mean = 9.4/10) and comparable with traditional face-to-face appointments (mean = 9.5/10). Patients were receptive to the use of telemedicine in certain situations, with patients strongly opposed to being told bad news via telemedicine (88%). Providers recommended the use of telemedicine in certain patient populations and reported largely equivalent workloads when compared with traditional consultations. Providers reported that telemedicine should be integrated into regular practice (66%), with patients echoing this indicating a preference for a majority of telemedicine appointments (57%). CONCLUSION: Telemedicine in sarcoma care is favorable from both clinician and patient perspectives. Utilization of telemedicine for patients with rare cancers such as sarcomas is an innovative approach to the delivery of care, especially considering the time and financial pressures on patients who often live a distance away from specialist centers. Patients and providers are keen to move toward a more flexible, mixed system of care.
PURPOSE: In Scotland, approximately 350 sarcoma cases are diagnosed per year and treated in one of the five specialist centers. Many patients are required to travel long distances to access specialist care. The COVID-19 pandemic brought a number of rapid changes into the care for patients with cancer, with increasing utilization of telemedicine. We aimed to evaluate how the utilization of telemedicine affects professionals and patients across Scotland and care delivery, at the Beatson West of Scotland Cancer Centre Sarcoma Unit. METHODS: Between June 8 and August 25, 2020, we invited patients and professional sarcoma multidisciplinary team members to participate in separate online anonymous survey questionnaires, to assess their attitudes toward telemedicine. Data were extracted, and descriptive statistics were performed. RESULTS: Patient satisfaction (n = 64) with telemedicine was high (mean = 9.4/10) and comparable with traditional face-to-face appointments (mean = 9.5/10). Patients were receptive to the use of telemedicine in certain situations, with patients strongly opposed to being told bad news via telemedicine (88%). Providers recommended the use of telemedicine in certain patient populations and reported largely equivalent workloads when compared with traditional consultations. Providers reported that telemedicine should be integrated into regular practice (66%), with patients echoing this indicating a preference for a majority of telemedicine appointments (57%). CONCLUSION: Telemedicine in sarcoma care is favorable from both clinician and patient perspectives. Utilization of telemedicine for patients with rare cancers such as sarcomas is an innovative approach to the delivery of care, especially considering the time and financial pressures on patients who often live a distance away from specialist centers. Patients and providers are keen to move toward a more flexible, mixed system of care.
Authors: Ying Taur; Mini Kamboj; Elizabeth V Robilotti; N Esther Babady; Peter A Mead; Thierry Rolling; Rocio Perez-Johnston; Marilia Bernardes; Yael Bogler; Mario Caldararo; Cesar J Figueroa; Michael S Glickman; Alexa Joanow; Anna Kaltsas; Yeon Joo Lee; Anabella Lucca; Amanda Mariano; Sejal Morjaria; Tamara Nawar; Genovefa A Papanicolaou; Jacqueline Predmore; Gil Redelman-Sidi; Elizabeth Schmidt; Susan K Seo; Kent Sepkowitz; Monika K Shah; Jedd D Wolchok; Tobias M Hohl Journal: Nat Med Date: 2020-06-24 Impact factor: 53.440
Authors: Alannah Smrke; Eugenie Younger; Roger Wilson; Olga Husson; Sheima Farag; Eve Merry; Aislinn Macklin-Doherty; Elena Cojocaru; Amani Arthur; Charlotte Benson; Aisha B Miah; Shane Zaidi; Spyridon Gennatas; Robin L Jones Journal: JCO Glob Oncol Date: 2020-07
Authors: Kiesha Prem; Yang Liu; Timothy W Russell; Adam J Kucharski; Rosalind M Eggo; Nicholas Davies; Mark Jit; Petra Klepac Journal: Lancet Public Health Date: 2020-03-25
Authors: Kamal S Saini; Marco Tagliamento; Matteo Lambertini; Richard McNally; Marco Romano; Manuela Leone; Giuseppe Curigliano; Evandro de Azambuja Journal: Eur J Cancer Date: 2020-09-02 Impact factor: 9.162
Authors: Paula D Koppel; Jennie C De Gagne; Sharron Docherty; Sophia Smith; Neil S Prose; Terri Jabaley Journal: J Med Internet Res Date: 2022-09-08 Impact factor: 7.076